ArticleVaccines2026

Cost-Effectiveness Analysis of Recombinant Zoster Vaccine at Age 50 for Chinese Adults with Mild Cognitive Impairment: A Modelling Study.

Yifei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.